Future of targeted therapy and genomic profiling

October 8, 2019 Off By Dino Mustafić

Annie Martin, Global Head of Presicion Medicine, has discussed the future of targeted therapy and genomic profiling, describing how to profile tumors with RNA and DNA sequencing.

Source: Novartis

TagsNovartis oncology

PharmaCann Provides Details on Termination of Transaction With MedMen and Additional Corporate Updates

ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full Enrollment In 300-Subject Multicenter Phase 2b Clinical Trial

Future of targeted therapy and genomic profiling

Share this:

Related